LIPIDIL

This brand name is authorized in Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Japan, Mexico

Active ingredients

The drug LIPIDIL contains one active pharmaceutical ingredient (API):

1 Fenofibrate UNII U202363UOS - FENOFIBRATE

Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. Read about Fenofibrate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIPIDIL NT Film coated tablet	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AB05	Fenofibrate	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 9022W, 9023X, 9246P, 9247Q
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 500214090032117, 500214090032217, 500220060045607, 500220090046307
Country: CA	Health Products and Food Branch	Identifier(s): 02241602, 02269074, 02269082
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 04031397, 04031405
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 360970612
Country: JP	医薬品医療機器総合機構	Identifier(s): 2183006F3023, 2183006F4020
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 349M98